SK Biopharmaceuticals Past Earnings Performance
Past criteria checks 0/6
SK Biopharmaceuticals has been growing earnings at an average annual rate of 33.7%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 24.1% per year.
Key information
33.7%
Earnings growth rate
39.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 24.1% |
| Return on equity | -11.0% |
| Net Margin | -9.3% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How SK Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 354,892 | -32,883 | 204,313 | 137,126 |
| 30 Sep 23 | 290,903 | -83,502 | 207,830 | 133,217 |
| 30 Jun 23 | 289,399 | -84,533 | 206,349 | 125,499 |
| 31 Mar 23 | 265,819 | -106,594 | 205,268 | 125,720 |
| 31 Dec 22 | 246,179 | -139,431 | 201,258 | 122,817 |
| 30 Sep 22 | 414,148 | -48,445 | 191,560 | 116,223 |
| 30 Jun 22 | 349,264 | -77,756 | 180,356 | 114,757 |
| 31 Mar 22 | 319,801 | -99,351 | 183,061 | 113,873 |
| 31 Dec 21 | 418,645 | 64,846 | 172,875 | 114,526 |
| 30 Sep 21 | 203,992 | -40,396 | 158,861 | 117,581 |
| 30 Jun 21 | 183,964 | -59,196 | 154,111 | 116,885 |
| 31 Mar 21 | 162,060 | -51,828 | 136,570 | 107,131 |
| 31 Dec 20 | 25,999 | -247,414 | 142,443 | 108,441 |
| 30 Sep 20 | 10,115 | -242,367 | 93,908 | 155,759 |
| 30 Jun 20 | 6,274 | -229,537 | 81,910 | 154,556 |
Quality Earnings: A326030 is currently unprofitable.
Growing Profit Margin: A326030 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A326030 is unprofitable, but has reduced losses over the past 5 years at a rate of 33.7% per year.
Accelerating Growth: Unable to compare A326030's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A326030 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.1%).
Return on Equity
High ROE: A326030 has a negative Return on Equity (-11.02%), as it is currently unprofitable.